Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun(Sungkyunkwan University), Lin Shen(Peking University), Manish A. Shah(Cornell University), Peter C. Enzinger(Dana-Farber Cancer Institute), Antoine Adenis(Institut de Recherche en Cancérologie de Montpellier), Toshihiko Doi(National Cancer Center Hospital East), Takashi Kojima(National Cancer Center Hospital East), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Zhigang Li(Shanghai Jiao Tong University), Sung‐Bae Kim(Ulsan College), Byoung Chul Cho(Yonsei University), Wasat Mansoor(The Christie Hospital), Shau-Hsuan Li(Kaohsiung Chang Gung Memorial Hospital), Patrapim Sunpaweravong(Prince of Songkla University), María Maqueda(Vall d'Hebron Institute of Oncology), Eray Goekkurt(University Cancer Center Hamburg), Hiroki Hara(Saitama Cancer Center), Luís Carlos Moreira Antunes(Universidade Federal de Santa Maria), Christos Fountzilas(Roswell Park Comprehensive Cancer Center), Akihito Tsuji(Kagawa University Hospital), Victor Castro Oliden(Instituto Nacional de Enfermedades Neoplásicas), Qi Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sukrut Shah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ken Kato(Tokyo National Hospital)
Cited by 1,563Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis